Objective: In a pilot study we have previously demonstrated successful transmission of glucometric values from continuous glucose monitoring (CGM) devices to a monitoring system at the nursing station (Glucose Telemetry System-GTS). In an ongoing study, we are evaluating whether use of GTS can reduce inpatient hypoglycemia compared to point of care (POC) capillary glucose testing, without increasing hyperglycemia.

Design: Twenty-four patients with DM2 at high risk for inpatient hypoglycemia were randomized to GTS (N=12 intervention group) or POC (N=12 standard of care). Nursing staff were asked to proceed with hypoglycemia preventative actions for GTS low glucose alarms set at <85 mg/dL. Subjects randomized to standard of care used “blinded” CGM. Mean percent time spent in hypoglycemia, hyperglycemia, and hypoglycemia event rates were evaluated.

Results: Twenty-one subjects were included in the analysis, 2 subjects withdrew due to minor bleeding at CGM insertion site and 1 subject had insufficient CGM data due to sensor failure. 30 GTS hypoglycemia alarms occurred in 7 different subjects. Overall percent time spent in hypoglycemia (≤70 mg/dL) was 0.18%±0.21 versus 1.64%±1.59 (p=0.056), and clinically significant hypoglycemia (<54mg/dL) was 0.01%±0.01 versus 0.48%±1.07 (p=0.135), between intervention and control groups, respectively. Rate of hypoglycemic episodes per day/per patient was 0.12±0.17 vs. 0.27±0.33 (p=0.19) for GTS and POC, respectively. Percent time spent in normoglycemia (70-179 mg/dL) was 52.04%±23.65 versus 52.92%±27.37 (p=0.94), while percent time in hyperglycemia (≥180 mg/dL) was 47.80%±23.65 versus 45.43%±28.05 (p=0.84), respectively.

Conclusion: In this preliminary analysis, subjects monitored by GTS had a non-statistically significant decrease in inpatient hypoglycemia compared to standard of care.

Disclosure

E. Spanakis: None. M. Satyarengga: None. L.G. Singh: None. L. Pinault: None. J.D. Sorkin: None. M. Zhan: None. G.E. Umpierrez: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc. Research Support; Self; AstraZeneca, Merck & Co., Inc., Novo Nordisk Inc., Sanofi US.

Funding

U.S. Department of Veterans Affairs (1I01CX001825-01)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.